Cargando…

Open label multicenter study of once weekly Etanercept 0.8 mg/kg in active polyarticular Juvenile idiopathic arthritis (JIA)

Detalles Bibliográficos
Autores principales:	Horneff, G, Minden, K, Foeldvari, I, Kuemmerle-Deschner, J, Thon, A, Girschick, H, Huppertz, HI
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334098/ http://dx.doi.org/10.1186/1546-0096-6-S1-P39

Ejemplares similares

Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab
por: Horneff, Gerd, et al.
Publicado: (2016)

Phase III, multi-centre, randomised, double blind, Placebo-controlled study for treatment of juvenile ankylosing spondylitis (AS) with Adalimumab
por: Horneff, G, et al.
Publicado: (2011)

Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry
por: Armaroli, Giulia, et al.
Publicado: (2020)

Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement
por: Horneff, Gerd, et al.
Publicado: (2012)

Biologic Therapies in Polyarticular Juvenile Idiopathic Arthritis. Comparison of Long‐Term Safety Data from the German BIKER Registry
por: Klein, Ariane, et al.
Publicado: (2019)

An in-depth analysis of young people's experience of their juvenile idiopathic arthritis (JIA) once receiving Etanercept
por: Livermore, P, et al.
Publicado: (2008)

Rituximab in ANA positive polyarticular juvenile idiopathic arthritis (JIA) with uveitis
por: Baildam, EM, et al.
Publicado: (2008)

Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis
por: Klotsche, Jens, et al.
Publicado: (2021)

Dynamic knee joint function in children with juvenile idiopathic arthritis (JIA)
por: Hansmann, Sandra, et al.
Publicado: (2015)

Indirect comparison of etanercept and abatacept efficacy and safety in patients with polyarticular juvenile idiopathic arthritis
por: Loskutova (Konopelko), OU, et al.
Publicado: (2014)

Polyarticular juvenile idiopathic arthritis (pJIA): clinical and serologic predictors of inactive disease (ID)
por: Meiorin, Silvia
Publicado: (2014)

Oral or Parenteral Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis
por: Bakry, Reima, et al.
Publicado: (2022)

Protocols on classification, monitoring and therapy in children’s rheumatology (PRO-KIND): results of the working group Polyarticular juvenile idiopathic arthritis
por: Horneff, Gerd, et al.
Publicado: (2017)

Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry
por: Horneff, Gerd, et al.
Publicado: (2017)

PReS-FINAL-2180: Efficacy and safety of tocilizumab (TCZ) in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA): 2-year data from CHERISH
por: De Benedetti, F, et al.
Publicado: (2013)

Methotrexate in oligoarticular persistent juvenile idiopathic arthritis
por: Horneff, Gerd, et al.
Publicado: (2014)

Outcome of children with oligoarticular juvenile idiopathic arthritis compared to polyarthritis on methotrexate- data of the German BIKER registry
por: Raab, A., et al.
Publicado: (2021)

Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapy
por: Goldzweig, Ofra, et al.
Publicado: (2011)

Progress in pediatric rheumatology: apprehend the opportunities of the future without forgetting the lessons from the past
por: Huppertz, Hans-Iko, et al.
Publicado: (2011)

Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven‐Year Interim Results
por: Brunner, Hermine I., et al.
Publicado: (2020)

No benefit of the combination therapy etanercept and methotrexate compared to etanercept mono therapy in juvenile idiopathic arthritis – a matched pair analysis
por: Schmeling, Heinrike, et al.
Publicado: (2012)

Administration of routine preventative vaccinations in children with polyarticular juvenile idiopathic arthritis receiving adalimumab
por: Minden, Kirsten, et al.
Publicado: (2014)

Concentration of survivin in children with oligo- and polyarticular juvenile idiopathic arthritis (JIA): diagnostic and prognostic value—a single-center study
por: Lipinska, Joanna, et al.
Publicado: (2021)

Distinct Effects of Methotrexate and Etanercept on the B Cell Compartment in Patients With Juvenile Idiopathic Arthritis
por: Glaesener, Stephanie, et al.
Publicado: (2014)

Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis
por: Ruperto, Nicolino, et al.
Publicado: (2021)

Meta-analysis confirms association between TNFA-G238A variant and JIA, and between PTPN22-C1858T variant and oligoarticular, RF-polyarticular and RF-positive polyarticular JIA
por: Kaalla, Merlyn J, et al.
Publicado: (2013)

Multicentric Castleman's Disease (CD) in juvenile idiopathic arthritis (JIA) treated with etanercept: coincidence or causal relationship?
por: Rossi, L, et al.
Publicado: (2008)

PReS-FINAL-2096: Herpes virus infections in patients with juvenile idiopathic arthritis (JIA) treated with etanercept
por: Nicolai, R, et al.
Publicado: (2013)

German evidence- and consensus-based guidelines 2011 for the treatment of juvenile idiopathic arthritis (JIA)
por: Dueckers, Gregor, et al.
Publicado: (2012)

Fluorescence optical imaging and musculoskeletal ultrasonography in juvenile idiopathic polyarticular disease before and during antirheumatic treatment - a multicenter non-interventional diagnostic evaluation
por: Klein, Ariane, et al.
Publicado: (2017)

German evidence and consensus based guidelines 2010 for the treatment of juvenile idiopathic arthritis (JIA)
por: Dueckers, G, et al.
Publicado: (2011)

Mitigated suppressive function of regulatory T cells (Treg) upon Th17-inducing cytokines in oligo- and polyarticular Juvenile Idiopathic Arthritis (JIA) patients
por: Holzer, Marie-Therese, et al.
Publicado: (2022)

Adherence, helpfulness and barriers to treatment in juvenile idiopathic arthritis – data from a German Inception cohort
por: Kirchner, Sabine, et al.
Publicado: (2023)

PReS-FINAL-2142: Predictors of persistent remission following etanercept (ETN) withdrawal in patients with juvenile idiopathic arthritis (JIA)
por: Perfetti, F, et al.
Publicado: (2013)

Safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis
por: Horneff, G, et al.
Publicado: (2015)

Advances in the treatment of polyarticular juvenile idiopathic arthritis
por: Webb, Kate, et al.
Publicado: (2015)

7.4 Improvements in individual disease components are sustained with long-term adalimumab therapy for polyarticular Juvenile Idiopathic Arthritis
por: Ruperto, N, et al.
Publicado: (2008)

Outcome of adult patients with JIA treated with the biosimilar Benepali(®): results of the biologic register JuMBO
por: Vollbach, Kristina, et al.
Publicado: (2022)

Similarities in clinical course and outcome between juvenile idiopathic arthritis (JIA)-associated and ANA-positive idiopathic anterior uveitis: data from a population-based nationwide study in Germany
por: Heiligenhaus, Arnd, et al.
Publicado: (2020)

DNase I levels in JIA – influence of anti-TNF (etanercept) therapy
por: Vojinovic, J, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_qqcrtq5vc2dqf8i2kalfm587o1